BRÈVE publiée le 19/01/2026 à 11:50, il y a 5 mois 7 jours Viromed Medical AG Advances with Ex-Vivo Lung Study Viromed Medical AG Cold Plasma Technology Ex-vivo Lung Study Preclinical Research Acceleration Saarland University Collaboration
COMMUNIQUÉ DE PRESSE publié le 19/01/2026 à 11:45, il y a 5 mois 7 jours Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval Viromed Medical AG's ex-vivo lung study with Saarland University and MHH is a significant milestone for research & approval, accelerating development processes Research Approval Viromed Medical AG Cold Plasma Technology Ex-vivo Lung Study
BRÈVE publiée le 15/01/2026 à 09:53, il y a 5 mois 11 jours Viromed Medical AG passe aux actions nominatives Actionnaires Bourse Viromed Medical AG Actions Nominatives Technologie Du Plasma Froid
BRÈVE publiée le 15/01/2026 à 09:53, il y a 5 mois 11 jours Viromed Medical AG Transitions to Registered Shares Shareholders Stock Exchange Viromed Medical AG Registered Shares Cold Plasma Technology
COMMUNIQUÉ DE PRESSE publié le 15/01/2026 à 09:48, il y a 5 mois 11 jours Viromed Medical AG switches to registered shares Viromed Medical AG converts share capital from bearer shares to registered shares to enhance transparency and direct shareholder communication. Stock trading to commence under new ISIN DE000A40VZN7 Stock Exchange Transparency Viromed Medical AG Registered Shares Bearer Shares
BRÈVE publiée le 07/01/2026 à 14:20, il y a 5 mois 19 jours Viromed AG partage une mise à jour stratégique sur ses avancées en matière de technologies médicales Partenariats Mondiaux Maladies Respiratoires Viromed Medical AG Dispositifs Médicaux Innovants Technologie Du Plasma Froid
BRÈVE publiée le 07/01/2026 à 14:20, il y a 5 mois 19 jours Viromed AG Shares Strategic Update on MedTech Advancements Respiratory Diseases Global Partnerships Innovative Medical Devices Viromed Medical AG Cold Plasma Technology
COMMUNIQUÉ DE PRESSE publié le 07/01/2026 à 14:15, il y a 5 mois 19 jours Viromed AG: Strategic Update on Operational Focus and Value Creation Viromed Medical AG provides strategic update on operational focus and value creation in the field of cold plasma technology and medical devices development Medical Devices Value Creation Viromed Medical AG Cold Plasma Technology Operational Focus
BRÈVE publiée le 28/11/2025 à 17:33, il y a 6 mois 28 jours Viromed Medical AG and HELLMUT RUCK GmbH Enter Exclusive Distribution Agreement Distribution Agreement Medical Technologies Viromed Medical AG HELLMUT RUCK GmbH Plasma Devices
BRÈVE publiée le 28/11/2025 à 17:33, il y a 6 mois 28 jours Viromed Medical AG et HELLMUT RUCK GmbH concluent un accord de distribution exclusive Accord De Distribution Viromed Medical AG Technologies Médicales HELLMUT RUCK GmbH Dispositifs Plasma
Publié le 26/06/2026 à 14:05, il y a 7 heures 17 minutes SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Publié le 26/06/2026 à 14:00, il y a 7 heures 22 minutes Dateline Chairman Invests $1.95 million through Options Exercise
Publié le 26/06/2026 à 13:00, il y a 8 heures 22 minutes Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Publié le 26/06/2026 à 12:45, il y a 8 heures 37 minutes Northern Dynasty Reports Oral Arguments Held
Publié le 26/06/2026 à 19:50, il y a 1 heure 31 minutes Name Change Completed for C Capital's Swiss Listed Entity, Ticker Symbol CCAP Goes Live
Publié le 26/06/2026 à 19:10, il y a 2 heures 11 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 26/06/2026 à 18:04, il y a 3 heures 17 minutes Turkiye Garanti Bankasi A.S.: Bond, subordinated debts, that can be included in the equity calculation debt instrument issuance CMB Application
Publié le 26/06/2026 à 18:00, il y a 3 heures 21 minutes PSP Swiss Property has sold the Richtipark in Wallisellen. The EBITDA guidance for the 2026 financial year has been increased.
Publié le 26/06/2026 à 18:00, il y a 3 heures 21 minutes VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M
